Constructive UK data

Less people going to hospital with Omicron infection compared to Delta infection. Apologies, I had a few technical problems with todays video Zoe update: Wednesday 22 December 2021 https://www.youtube.com/watch?v=CIGC310hPoI https://covid.joinzoe.com/post/everything-we-know-so-far-about-omicron https://joinzoe.com/learn/category/covid https://joinzoe.com/learn/new-omicron-variant 144,284 new daily symptomatic cases of COVID in the UK In people who have had at least 2 vaccine doses 56,346 new daily symptomatic cases in the UK 70% + cases in England are now Omicron The UK R value, 1.2 R value in London is 1.5. From 17,000 omicron cases Runny nose Headache Fatigue (either mild or severe) Sneezing Sore throat (NHS test and trace is not telling users of their Omicron status anymore) Report 50 - Hospitalisation risk for Omicron cases in England https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/ https://www.theguardian.com/world/2021/dec/22/risk-of-hospital-stay-40-lower-with-omicron-than-delta-uk-data-suggests Differences in the risk of hospitalisation between Omicron and Delta 1st to 14th December inclusive Analysed data from all PCR-confirmed SARS-CoV-2 cases in England Cases S-gene Target Failure (SGTF) and genetic data Omicron, n = 56,000 Delta, n = 269,000 Reduction in the risk of hospitalisation for Omicron relative to Delta infections Endpoint, any attendance at hospital 20-25% reduced risk Endpoint, hospitalisation lasting 1 day or longer 40-45% reduced risk These reductions must be balanced against the larger risk of infection with Omicron, due to the reduction in protection provided by both vaccination and natural infection. Intrinsic differences in severity between Omicron and Delta Omicron may result in slightly less severe disease From the few neither previously infected nor vaccinated, risk of hospitalisation, 11% lower for Omicron versus Delta Level of protection from previous infection Reduces the risk of any hospitalisation by 50% Reduces the risk of a hospital stay of 1+ days by 61% Risk of symptomatic infection with omicron More protection after PF/MD than AZ Hospitalisation risk by vaccination state AstraZenca (AZ) (doses 1 and 2) Omicron hazard ratios are lower than for Delta Pfizer or Moderna (PF/MD) (doses 1 and 2) Omicron hazard ratios are similar to those seen for Delta Conclusions, after at least 2 vaccine doses Protection against omicron infection has been largely lost Remain substantially protected against hospitalisation Does not substantially change Sage modelling Pointing to 3,000 daily hospitalisations in England at the peak next month Omicron cases in Scotland, Eave II study (Early Pandemic Evaluation and Enhanced Surveillance of COVID-19) https://www.sciencemediacentre.org/data-from-scotland-on-omicron-severity-from-the-eave-ii-study/ https://www.ed.ac.uk/usher/eave-ii/key-outputs/our-publications/severity-of-omicron-variant-of-concern-and-vaccine https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness- Hospital data from 23 November to 19 December Risk of hospitalisation, 70% lower with Omicron than Delta. 15 hospitalisations with Omicron Opposed to the 47 admissions from delta (Expected given the characteristics of those infected) First case of Omicron confirmed by viral sequencing was recorded in Scotland on November 23, 2021 By December 19, 2021, there were 23,840 S gene negative cases. These S gene negative cases were predominantly in the age group 20-39 (11,732; 49.2%). Reinfections, more than 10 times more likely with omicron Omicron positive cases that were reinfections, 7.6% Delta cases that were reinfections, 0.7% The third/booster vaccine dose was associated with a 57% reduction in the risk of symptomatic Learn more about your ad choices. Visit megaphone.fm/adchoices